Los Angeles Capital Management LLC Has $120.47 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Posted by Brian Himes on Jun 7th, 2026

Los Angeles Capital Management LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 41.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,665 shares of the company’s stock after acquiring an additional 56,230 shares during the quarter. Los Angeles Capital Management LLC’s holdings in IDEXX Laboratories were worth $120,469,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Beacon Investment Advisory Services Inc. boosted its holdings in shares of IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares in the last quarter. Procyon Advisors LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $1,966,000. NEOS Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after acquiring an additional 13,599 shares in the last quarter. Finally, Diversified Trust Co. boosted its holdings in shares of IDEXX Laboratories by 223.5% in the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on IDXX shares. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $751.00.

Check Out Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Price Performance

IDXX stock opened at $562.16 on Friday. The stock has a 50-day moving average price of $563.05 and a two-hundred day moving average price of $632.14. The stock has a market cap of $44.34 billion, a PE ratio of 41.40, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.